DDInter702 DDInter1376
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Etoposide {u} (Compound) resembles {v} (Compound) Podofilox
Etoposide {u} (Compound) treats {v} (Disease) urinary bladder cancer
Etoposide {u} (Compound) binds {v} (Gene) GSTT1
Etoposide {u} (Compound) upregulates {v} (Gene) COL11A1
Etoposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Etoposide {u} (Compound) downregulates {v} (Gene) AURKB
Etoposide {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Etoposide (Compound) resembles Podofilox (Compound)
Etoposide (Compound) treats urinary bladder cancer (Disease)
Etoposide (Compound) binds GSTT1 (Gene)
Etoposide (Compound) upregulates COL11A1 (Gene)
Etoposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Etoposide (Compound) downregulates AURKB (Gene)
Etoposide (Compound) causes Necrolysis epidermal (Side Effect)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Etoposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept